Therapeutic approaches targeting midkine suppress tumor growth and lung metastasis in osteosarcoma

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Midkine (MK) is implicated in tumorigenesis, but its specific role and therapeutic potential in osteosarcoma remain largely undefined.
• Understanding MK's function is crucial for developing novel treatment strategies for this bone cancer.

Purpose of the Study:

• To investigate the biological function of Midkine (MK) in osteosarcoma.
• To evaluate the potential of targeting MK as a therapeutic strategy for osteosarcoma treatment.

Main Methods:

• Assessed MK expression levels in osteosarcoma tissues.
• Utilized small interfering RNA (siRNA) for MK knockdown in osteosarcoma cells.
• Administered recombinant MK to study its effect on cell proliferation.
• Employed anti-MK monoclonal antibody (anti-MK mAb) to inhibit MK signaling in vitro and in vivo.
• Evaluated the impact of MK inhibition on lung metastasis in a xenograft transplantation model.

Main Results:

• Osteosarcoma tissues exhibited significantly high MK expression.
• MK knockdown induced apoptosis in osteosarcoma cells, while recombinant MK enhanced cell proliferation.
• Inhibition of MK signaling via anti-MK mAb suppressed osteosarcoma cell growth both in vitro and in vivo.
• Targeting MK function markedly reduced lung metastasis in a preclinical model.

Conclusions:

• Midkine (MK) promotes osteosarcoma cell proliferation and metastasis.
• Inhibition of MK signaling, particularly using anti-MK monoclonal antibody (anti-MK mAb), demonstrates significant therapeutic potential.
• Targeting MK represents a promising strategy for the treatment of osteosarcoma.